Risk factors | Univariable analysis HR (95% CI) | p value | Multivariable analysis HR (95% CI) | p value |
---|---|---|---|---|
Age years | 1.02 (0.99–1.04) | 0.142 | 1.02 (0.99–1.02) | 0.230 |
Female sex | 0.54 (2.27–1.08) | 0.080 | 0.52 (0.24–1.14) | 0.104 |
Clinical presentationa | ||||
DCM and/or heart failure | 1.25 (0.65–2.43) | 0.500 | ||
Ventricular arrhythmias | 0.93 (0.32–2.70) | 0.901 | ||
Renal insufficiency | 2.23 (1.16–4.31) | 0.017 | 2.19 (1.05–4.55) | 0.036 |
LVEF | 0.98 (0.96–0.99) | 0.027 | 1.00 (0.97–1.03) | 0.781 |
LVEDVI | 1.01 (1.00–1.02) | 0.009 | 1.00 (0.99–1.01) | 1.180 |
Myocardial segments with enhancementb | ||||
2 segments | 2.26 (0.98–5.19) | 0.056 | 2.32 (0.97–5.83) | 0,058 |
≥ 3 segments | 2.97 (1.26–6.95) | 0.012 | 2,71 (1.04–7.04) | 0,040 |
Aspirin | 1.32 (0.72–2.44) | 0.366 | ||
Dual antiplatelet therapy | 0.77 (0.42–1.43) | 0.417 | ||
Oral anticoagulants | 1.43 (0.77–2.65) | 0.257 | ||
Beta-blockers | 0.15 (0.62–2.14) | 0.663 | ||
ACEI/ARB | 1.12 (0.58–2.16) | 0.370 | ||
Statins | 0.78 (0.42–1.45) | 0.436 |